Regulatory Affairs

11
May
Back view business woman raising hand for asking speaker for question and answer concept in meeting room for seminar

IQVIA VP Discusses the Market – Including Factors Impacting Patient Compliance

We all know that the most expensive prescription is the one the patient does not take.  Certainly, there are several factors that impact the decision for a patient to fill a prescription.  Failure to comply with medication directions can also impact the health of the patient.  These failures to comply can lead to more expensive […]

Read More
07
May

Fast on the Trigger COVID-19 Response for Shortage Drugs

Looking over the daily COVID-19 updates from the FDA (here), I noticed that the OGD had approved “two generic drugs indicated to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation: succinylcholine chloride injection USP 200 mg/10 mL and cisatracurium besylate injection USP 20 mg/10 mL.”  Glad to see that […]

Read More
06
May
Businessman examines a tablet with a magnifying glass. Concept of internet security

Getting Ready for FY 2021 PDUFA Program Fees – “Dear Colleague” Letter Arrives in the Mail

The FDA has sent a “Dear Colleague” letter (here) to NDA holders to get ready for the start of FY 2021 on October 1, when the program fees (previously called “product fees” in previous iterations of PDUFA) will be due for each product (up to 5 in each application) marketed by the application holder.  The […]

Read More
04
May

Silver Ain’t No Silver Bullet – It’s Fraud, Says DOJ

The FDA posted a Department of Justice press release discussing a temporary injunction against a Utah firm from selling and marketing silver products as a prevention and cure for the corona virus. The press release states “The Department of Justice will take swift action to protect consumers from those who would recklessly exploit this public […]

Read More
01
May
Warning sign

Black Box Warning Added to Singulair and Montelukast Generics Labeling

The FDA has added a Black Box warning to the popular drug montelukast (brand name Singulair).  A black box warning is one of FDA’s most significant label warnings, and in this case, there are recommendations to potentially change therapeutic decisions based on the severity of the diseases and the potential risk benefit The new warning […]

Read More
29
Apr

BE Studies and COVID 19 Pandemic – What’s an Applicant To Do?

Clearly, the COVID-19 pandemic has had an impact on clinical studies during drug development, and that includes in vivo bioequivalence studies.  The FDA has reacted to the potential issues it sees by issuing a statement entitled Bioequivalence Studies for Submission in ANDAs during the COVID-19 Pandemic (here). In discussing the types of challenges that may […]

Read More
29
Apr

Jam the Scammers – A Group of White Hats Step Up – and You Can’t Even See Them at Work

With a sense of honor and the common good, last month some scammers “promised to refrain” from attacking healthcare operations during the COVID-19 pandemic.  Unfortunately, some people believed them! I get it.  This virus impacts every one of us.  We all would like to believe that, in this current environment, people will step up and […]

Read More
24
Apr
Caution Tape

Propofol Guidance on Use in Shortage Situations -An Eerie Remembrance

Propofol is an excellent anesthetic, relatively safe with a fast induction time and relatively quick recovery time.  It is used in all types of surgical and non-surgical procedures (including intubation and time on a vent if the patient is in distress).  With all the COVID 19 cases and the resultant hospitalizations and ICU stays, the […]

Read More
1 58 59 60 163